ReviewCurrent opinion in HIV and AIDS2018
Cross-reactivity of HIV vaccine responses and the microbiome.
Review in Current opinion in HIV and AIDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.PloS one · 2019Trial
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine.Cell host & microbe · 2025Article
- Article
- Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.AIDS research and human retroviruses · 2023Article
- Unexpectedly higher levels of anti-orthopoxvirus neutralizing antibodies are observed among gay men than general adult population.BMC medicine · 2023Article
- Article
- Novel Vaccine Strategies and Factors to Consider in Addressing Health Disparities of HPV Infection and Cervical Cancer Development among Native American Women.Medical sciences (Basel, Switzerland) · 2022Review
- Review
- A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.Nature communications · 2022Article
- Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.Journal of the International AIDS Society · 2021Review
- Review
- Review
- The Roles of T cells in Bladder Pathologies.Trends in immunology · 2021Review
- Host Transcriptome and Microbiota Signatures Prior to Immunization Profile Vaccine Humoral Responsiveness.Frontiers in immunology · 2021Article
- The Impact of the Microbiome on Immunity to Vaccination in Humans.Cell host & microbe · 2020Review
- A highly polarized TNature immunology · 2020Article
- Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans.Cell reports. Medicine · 2020Article
- Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.Cell reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewA successful human immunodeficiency virus-type 1 (HIV-1) vaccine will require immunogens that induce protective immune responses. However, recent studies suggest that the response to HIV-1 and perhaps other viruses may be altered by immune system exposure to intestinal microbiota-antigens. This review will discuss select aspects of these studies. RECENT
findingsNaïve CD4 T and B cell repertoires can be imprinted by intestinal microbiota-antigens to respond to virus epitopes prior to virus infection. A multiclade envelope (Env) gp145 DNA prime, recombinant adenovirus type 5 boost vaccine tested in a HIV Vaccine Trials Network (HVTN) phase IIb human vaccine efficacy trial (HVTN 505) induced a dominant gp41-reactive antibody response that was non-neutralizing and cross-reactive with intestinal microbiota. This vaccine regimen also induced a dominant gp41-reactive, intestinal microbiota-cross-reactive gp41 antibody response in neonatal and adult Rhesus macaques. Studies of naïve CD4 T cells have demonstrated cross-reactivity to both HIV-1 and influenza peptides. SUMMARY: HIV-1 Env vaccine-induced CD4 T and B cell responses can originate from a pool of intestinal microbiota-cross-reactive immune cells. Moreover, intestinal microbiota-cross-reactive HIV-1 Env antibodies are ineffective in protection against HIV-1 infection. Thus, intestinal microbiota-imprinting of the B cell repertoire may be one of several roadblocks to the induction of protective HIV-1 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.